PORVAIR PLC

M&A Activity • Feb 26, 2021

National Storage Mechanism | Additional information

RNS Number : 4278Q

Porvair PLC

26 February 2021

26 February 2021

Porvair plc ("Porvair" or "The Group")

Acquisition of Kbiosystems Limited

Porvair, the specialist filtration, laboratory and environmental technologies group, is pleased to announce the acquisition of Kbiosystems Limited ("Kbiosystems").

Kbiosystems is based in Basildon, UK and specialises in the design and manufacture of laboratory instruments, with particular expertise in automated microplate handling systems.  On 25 February 2021, the Group acquired 100 per cent. of the share capital of Kbiosystems, which reported revenue of £3.8 million in the year ended 31 March 2020.

Kbiosystems will continue to operate from its existing premises and will be integrated into the Group's Laboratory division.

Commenting on the acquisition, Ben Stocks, Chief Executive, said:

"We are delighted that Kbiosystems has joined the Group.  We have known the business for many years and there is a good fit between our laboratory consumables business and Kbiosystems instrument automation expertise.  Together the businesses have a compelling offering for laboratories seeking to automate their sample testing processes."

For more information, contact:

Porvair plc
Ben Stocks, Chief Executive	01553 765 500
Chris Tyler, Group Finance Director	01553 765 500
Buchanan Communications	0207 466 5000
Charles Ryland /Stephanie Watson

Notes to Editors

Porvair is a group of specialist filtration, separation and environmental technologies businesses.  Its products are used in a range of niche filtration and separation markets, and are derived from its expertise in the design and manufacture of filtration and separation systems.  It is organised into three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQDGGDDLDDDGBU